Unveiling the Economic Burden of Untreated Mental Illness
By Staff Writer
October 25, 2023
A Better Understanding of the Financial Burden
In the United States, roughly one in five people will struggle with some form of mental illness in any given year; yet, less than half of those people will obtain the appropriate care. The COVID-19 pandemic has further compounded the absence of effective mental health services, leaving millions of people with unmet treatment needs. Untreated mental illness has consequences that reach beyond the person who suffers from it. These consequences include a decrease in the individual’s quality of life, productivity, and overall health. They may even result in work difficulties or engagement with the legal system. Because of this, individuals, families, and society as a whole are forced to shoulder a tremendous amount of additional financial strain.
The Requirement for Detailed Information
Policymakers need comprehensive data on the financial consequences of untreated mental illness to address this issue effectively. Previous research has explored the financial impact of various mental diseases. However, no study has fully examined the costs of untreated disease. Health insurers, governments, and employers need this data. It helps them understand the total economic burden of untreated mental illness. It also shows the potential cost savings from improving access to and delivering mental health care.
A Case Study: Indiana
A recent study was conducted in Indiana with the purpose of estimating the economic impact of untreated mental illness in the state. The findings of this study will be used to inform legislation and programs that are designed to address this issue. The research presented a methodology at the societal level to evaluate both direct and indirect costs associated with untreated mental diseases. The research estimated the individual, family, workplace, and community expenses associated with untreated mental disorders. The findings were shocking: it was predicted that Indiana bears a total annual economic burden of $4.2 billion due to untreated mental illness.
Taking Steps to Address the Problem
The importance of early detection, counseling, and access to mental health services and therapies is driven home by these findings. Not only could these approaches increase the productivity of individuals and minimise their need for social services, but they also had the potential to drastically cut the expenses associated with incarceration and homelessness. It has been argued that telehealth might be used as a viable means to improve access to therapy, and recent regulatory changes in Indiana have made it possible for Medicaid to compensate providers for providing telehealth services.
The Duty That Falls on Policymakers
Policymakers have an important part to play in removing obstacles to seeking and getting treatment, such as providing care that is sensitive to cultural norms and addressing the stigma that is associated with seeking therapy. They are able to secure improved long-term outcomes and overall cost savings for health care systems as well as society as a whole when they embrace a comprehensive strategy to recognising and resolving the economic burden of untreated mental illness. This is possible because of the comprehensive nature of the approach.
🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?
Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.
Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.
🌟 How can personalized medicine transform breast cancer treatment in Spain?
The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.
Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.
🌟 Are we on the brink of transforming breast cancer treatment?
NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.
Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
